SESSION XIII: CELLULAR THERAPY 

Session Chairs: Roni Shouval, MD, PhD and Sairah Ahmed, MD

Multimodal Approach to Predict Cellular Therapy Outcome | Roni Shouval, MD, PhD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

AI Agents Transforming Care in Bone Marrow Transplantation | Amin Turki, MD, PhD | University Hospitals Essen, Essen, Germany

Debate: Car T Cells Are the Best Strategy for Relapsed DLBCL | Yi Lin, MD, PhD | Mayo Clinic Rochester, Rochester, Minnesota, USA

Debate: Bispecific Abs Are the Best Strategy for Relapsed DLBCL | Jennifer Crombie, MD | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Novel Engineered NK Cell Trials | May Daher, MD | MD Anderson Cancer Center, Houston, Texas, USA

Oral Abstract | CT-230: Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study | Reem Karmali, MD, MS | Northwestern University, Chicago, Illinois, USA

Oral Abstract | CT-1498: A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (Car) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Krish Patel, MD | Sarah Cannon Research Institute, Nashville, Tennessee, USA